Expression of mitotic Aurora/Ipl1p-related kinases in renal cell carcinomas: an immunohistochemical study

Hidetoshi Ehara1, Shigeaki Yokoi, Masayoshi Tamaki

  • 1Department of Urology, Gifu University School of Medicine, 40 Tsukasa, Gifu 500-8705, Japan. h-ehara@cc.gifu-u.ac.jp

Urological Research
|September 19, 2003
PubMed

Insights

This study investigated Aurora/Ipl1p-related kinases (AIRK1, AIRK2, AIRK3) in human renal cell carcinoma. High expression of AIRK1 and AIRK3, and correlation of AIRK2 with proliferation, suggest a role in kidney cancer development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Aurora/Ipl1p-related kinases (AIRK1, AIRK2, AIRK3) are oncogenic serine/threonine kinases.
  • These kinases are involved in cell cycle regulation, chromosome segregation, and cytokinesis.

Purpose of the Study:

  • To examine the expression of AIRK1, AIRK2, and AIRK3 in human renal cell carcinomas.
  • To investigate the potential role of AIRK subfamily expression in renal cell carcinoma tumorigenesis.

Main Methods:

  • Immunohistochemistry was used to assess AIRK subfamily expression in 64 renal cell carcinoma specimens.
  • Correlation between AIRK2 staining and proliferating cell nuclear antigen (PCNA) labeling was analyzed.

Main Results:

  • AIRK1, AIRK2, and AIRK3 immunostaining was detected in 95%, 47%, and 98% of renal cell carcinoma specimens, respectively.
  • AIRK2 staining showed a positive correlation with PCNA labeling in specimens from the same patient.
  • This study presents the first description of AIRK isozyme immunostaining in human renal cell carcinoma.

Conclusions:

  • AIRK subfamily expression is prevalent in human renal cell carcinoma.
  • The observed expression patterns and correlation with proliferation markers suggest that AIRK kinases may contribute to renal cell carcinoma development.